These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 23192654)
21. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Kluza J; Marchetti P; Gallego MA; Lancel S; Fournier C; Loyens A; Beauvillain JC; Bailly C Oncogene; 2004 Sep; 23(42):7018-30. PubMed ID: 15273722 [TBL] [Abstract][Full Text] [Related]
22. The role of pixantrone in the treatment of non-Hodgkin's lymphoma. Borchmann P; Schnell R Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797 [TBL] [Abstract][Full Text] [Related]
23. Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin. Longo M; Della Torre P; Allievi C; Morisetti A; Al-Fayoumi S; Singer JW Reprod Toxicol; 2014 Jul; 46():20-30. PubMed ID: 24602559 [TBL] [Abstract][Full Text] [Related]
24. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. El-Helw LM; Hancock BW Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631 [TBL] [Abstract][Full Text] [Related]
26. Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase. Brück TB; Brück DW Biochimie; 2011 Feb; 93(2):217-26. PubMed ID: 20887767 [TBL] [Abstract][Full Text] [Related]
27. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Mushlin PS; Cusack BJ; Boucek RJ; Andrejuk T; Li X; Olson RD Br J Pharmacol; 1993 Nov; 110(3):975-82. PubMed ID: 8298821 [TBL] [Abstract][Full Text] [Related]
28. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Minotti G; Saponiero A; Licata S; Menna P; Calafiore AM; Teodori G; Gianni L Clin Cancer Res; 2001 Jun; 7(6):1511-5. PubMed ID: 11410484 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity. Lehotay DC; Levey BA; Rogerson BJ; Levey GS Cancer Treat Rep; 1982 Feb; 66(2):311-6. PubMed ID: 6120040 [TBL] [Abstract][Full Text] [Related]
31. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422 [TBL] [Abstract][Full Text] [Related]
32. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Patel KJ; Trédan O; Tannock IF Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920 [TBL] [Abstract][Full Text] [Related]
33. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366 [TBL] [Abstract][Full Text] [Related]
34. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice. Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424 [TBL] [Abstract][Full Text] [Related]
35. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. Doroshow JH; Davies KJ J Biol Chem; 1986 Mar; 261(7):3068-74. PubMed ID: 3005279 [TBL] [Abstract][Full Text] [Related]
36. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Boyle EM; Morschhauser F Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061 [TBL] [Abstract][Full Text] [Related]
37. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats. Cusack BJ; Musser B; Gambliel H; Hadjokas NE; Olson RD Cancer Chemother Pharmacol; 2003 Feb; 51(2):139-46. PubMed ID: 12647015 [TBL] [Abstract][Full Text] [Related]
38. [Cardiotoxicity due to prolonged administration of THP (2"R-4'-O-tetrahydropyranyl-adriamycin)]. Suzuki M; Hirono M; Majima H Gan To Kagaku Ryoho; 1997 Oct; 24(13):1993-9. PubMed ID: 9350248 [TBL] [Abstract][Full Text] [Related]
39. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats. Vaidyanathan S; Boroujerdi M Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735 [TBL] [Abstract][Full Text] [Related]
40. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]